ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.04B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.45M
Average 1.66M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.3% (5yr)5 analysts |
| Revenue | N/A | N/A | +27.5% | +11.2% (5yr)12 analysts |
| Net Income | N/A | N/A | N/A | +1.3% (5yr)12 analysts |
| EBIT | N/A | N/A | N/A | +38.2% (5yr)12 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.5% over three years. Forward estimates point to EBIT at +38.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Praxis Precision Medicines, Inc. NASDAQ:PRAX | $9.17B | $328.13 | Not rated | -25.0 | +89.47% |
Axsome Therapeutics, Inc. NASDAQ:AXSM | $7.45B | $141.69 | Not rated | -68.6 | -5.32% |
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | $43.01 | Not rated | -21.4 | +153.58% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -12.14% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +87.35% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -26.02% |
MapLight Therapeutics, Inc. NASDAQ:MPLT | $308.98M | $7.25 | Not rated | -2.8 | -51.69% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $241.27M | $3.99 | Not rated | -1.4 | -24.17% |
Anavex Life Sciences Corp. NASDAQ:AVXL | $86.53M | $0.93 | Not rated | -5.9 | -78.94% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -85.30% |
Continue the stock analysis
Jump to another research area for this company.